Incidence of serious adverse events was similar between treatment groups ( QVA@ , @ of @ -LSB- @ % -RSB- ; SFC @ of @ -LSB- @ % -RSB- ) ; COPD worsening was the most frequent serious adverse event ( one of @ -LSB- @ % -RSB- and three of @ -LSB- @ % -RSB- , respectively ) .